Parkin et al. Ca cancer j clin. 2005;55: 74-108. Parkin et al. Ca cancer j clin. 2005;55: 74-108

Parkin et al. CA Cancer J Clin. 2005;55:74-108.

• Parkin et al. CA Cancer J Clin. 2005;55:74-108.

Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy

• Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy

• 80%-85% respond to first-line therapy
• Newer regimens including molecular targeted therapy are under investigation
• Most patients develop disease recurrence within 2 years of diagnosis

• Long-term remission dependent upon surgical/chemotherapy approach

• Several agents active in the second-line setting, resulting in improved progression-free and overall survival

Patient/disease factors – heterogeneous disease

• Patient/disease factors – heterogeneous disease

• Prior complete debulking or initial FIGO I/II
• Ascites > 500ml
• Performance status ECOG 0
• Age
• Presence/absence of symptoms
• Platin-based chemotherapy
• Parenchymal involvement
• Relapse-free vs treatment-free interval (TFI)

Patient/disease factors – heterogeneous disease

• Patient/disease factors – heterogeneous disease

• Prior complete debulking or initial FIGO I/II
• Ascites > 500ml
• Performance status ECOG 0
• Age
• Presence/absence of symptoms
• Platin-based chemotherapy
• Parenchymal involvement
• Relapse-free vs treatment-free interval (TFI)

E. Pujade-Lauraine et al.

• E. Pujade-Lauraine et al.

Gadducci et al. Anticancer Res. 2001;21:3525-3533.

• Gadducci et al. Anticancer Res. 2001;21:3525-3533.

Bookman. The Oncologist. 1999;4:87-94.

• Bookman. The Oncologist. 1999;4:87-94.

Cure

• Cure

• Survival prolongation

• Achievement of durable objective response

• Improvement in cancer-related symptoms

• Maintenance of quality of life (tend to correlate with response rate)

• Delayed time to (symptomatic) disease progression